Astrazeneca: EU-Zulassung für Tagrisso gegen weitere Lungenkrebsform
AMSTERDAM/LONDON (dpa-AFX) - Der britische Pharmakonzern Astrazeneca darf sein Lungenkrebsmedikament Tagrisso in der EU in einer weiteren Indikation verkaufen.…
81,000€
4,52%
Echtzeit-Aktienkurs ASTRAZENECA DL-,25 SP.ADR
Bid:
Ask:
Nachrichten zur ASTRAZENECA DL-,25 SP.ADR Aktie
AZNs Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable…
Is AstraZeneca Stock a Buy?
U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were…
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and…
Beijing Woos AstraZeneca for Investment While Probe Continues
Beijing’s mayor called on AstraZeneca Plc to expand its research and development investment in the Chinese capital, signaling that a…